

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Kobayashi et al.

Art Unit: Unassigned

Application No. Unassigned

Examiner: Unassigned

Filed: July 20, 2001

For: METHOD OF SUPPRESSING ONGOING
ACUTE ALLOGRAFT REJECTION

PENDING CLAIMS AFTER ENTRY OF PRELIMINARY AMENDMENT

1. A method of suppressing ongoing acute allograft rejection, which method comprises administering to a host experiencing ongoing acute allograft rejection an interleukin-10 (IL10) inhibitor and an interleukin-2 (IL2) inhibitor in amounts effective to rescue the allograft from ongoing acute rejection.
2. The method of claim 1, wherein said IL10 inhibitor is an IL10 antagonist.
3. The method of claim 2, wherein said IL10 antagonist is an anti-IL10 antibody.
4. The method of claim 2, wherein said IL10 antagonist is an IL10 receptor antagonist.
5. The method of claim 4, wherein said IL10 receptor antagonist is an anti-IL10 receptor antibody.
6. The method of claim 1, wherein said IL10 inhibitor is a compound which blocks the upstream or downstream signals of IL10.
7. The method of claim 1, wherein said IL10 inhibitor and said IL2 inhibitor are administered during acute rejection.
8. The method of claim 1, wherein said allograft is selected from the group consisting of heart, kidney, liver, lung, pancreas, bladder, small intestine, and skin.

In re Appln. of Kobayashi et al.
Application No. Unassigned
Attorney Docket: 212653

9. The method of claim 1, wherein the inhibitor of IL2 is an inhibitor of IL2 mRNA transcription.

10. The method of claim 9, wherein said inhibitor of IL2 mRNA transcription is cyclosporin A (CsA).

13. A method of suppressing ongoing acute allograft rejection, which method comprises administering to a host experiencing ongoing acute allograft rejection, which is due to insufficient immunosuppression by an IL2 inhibitor, an IL10 inhibitor in an amount effective to rescue the allograft from ongoing acute rejection.